Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jian Shen Pian
- Development stage
- Phase 3
- Lead developer
- Jiangsu Kanion Pharmaceutical
- Administration
- Oral
01
Overview
Jian Shen Pian is a traditional Chinese medicine (TCM) oral tablet developed by Jiangsu Kanion Pharmaceutical for the treatment of chronic nephritis, specifically targeting the Pi-Shen (Spleen-Kidney) deficiency pattern. The formulation is designed to reduce subnephrotic proteinuria and improve clinical symptoms associated with chronic glomerulonephritis. In clinical studies, it has been evaluated for its ability to tonify the spleen and kidney, resolve dampness, and improve renal function. A Phase 3 trial (CTR20130167) in China compared Jian Shen Pian against Shenyanshu capsules in adult patients to establish its safety and efficacy profile.
- Brand names
- Jian Shen Pian
- Other names
- Jianshen PianJianshen Tablet
Beyond the preview
Go deeper on Jian Shen Pian.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jian Shen Pian.